Dyne Therapeutics

One month to go until World Duchenne Awareness Day on September 7. This year’s theme is “Family: The Heart of Care.” From caregiving to advocacy, family members play a vital role in the lives of individuals living with Duchenne muscular dystrophy (DMD). Explore how you can get involved and stay tuned for the premiere of a powerful new documentary from the World Duchenne Organization sharing stories from families around the world: https://bit.ly/3UFKo6u #WDAD2025

We were honored to host Dr. Kirk Taylor, President and CEO of the Massachusetts Life Sciences Center, for our FORCEs in Biotech series. Dr. Taylor shared a compelling journey from neurologist to biotech executive to public sector leader, reminding us of the power of adaptability and authentic leadership. He reminded us how essential collaboration, trust and purpose are, especially when preparing to launch new therapies. From AI to DEI to early STEM education, he also touched on the important role the Massachusetts Life Sciences Center plays in our biotech ecosystem. Thank you Kirk Taylor, MD for your time, honesty and leadership.

The FDA has granted Breakthrough Therapy Designation to DYNE-251 for the treatment of patients with #Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. Based on data from the DELIVER trial, DYNE-251 has the potential to address a significant unmet need for people living with DMD by delivering sustained functional improvement. Read more: https://bit.ly/4fly055

Happy National Intern Day! Today we’re celebrating the incredible contributions of our Dynamo interns and co-ops who bring curiosity, energy and a shared passion for advancing transformative therapies for people living with genetically driven neuromuscular diseases. Their work supports our goal of delivering meaningful functional improvement to patients. Thank you for all your hard work, fresh perspectives and commitment to our mission!

Today we shared our Q2 2025 results, showcasing continued momentum across our pipeline and upcoming milestones. Read to learn more: https://bit.ly/3U5fi8a

A big congratulations to our #Dynamos who were recently promoted! Your hard work, dedication and passion for our mission continue to drive Dyne forward as we work to deliver functional improvement for people living with genetically driven neuromuscular diseases.

This July, join the Myotonic Dystrophy Foundation (MDF) for Myotonic Dystrophy in Motion Awareness Month, an initiative to educate and inspire those with myotonic dystrophy (DM) about the power of movement. MDF will host weekly activities, expert webinars and offer opportunities to connect. Learn more and get involved: https://bit.ly/40lcXJZ

On Dyne Science Day, our #Dynamos came together to learn from our scientists about the research, insights and innovation driving our goal to deliver functional improvement for people living with neuromuscular diseases. Thank you to our Scientists for cultivating a spirit of curiosity and fearless innovation.

This #WorldFSHDDay, we’re proud to stand with the FSHD Society and the FSHD community to raise awareness of facioscapulohumeral muscular dystrophy and one of its most visible symptoms: the loss of the ability to smile. Join us in spreading awareness. Snap an orange slice selfie and learn more: https://bit.ly/3xmOSXP

RNA therapeutics are transforming the landscape of drug development. Dyne’s Chief Innovation Officer, Oxana Beskrovnaya, will join leaders across industry and academia at #BIO2025 to discuss what’s driving this momentum. The panel will explore the breakthroughs powering the “RNAissance” and how innovation and investment are accelerating the next wave of RNA-based medicines. Learn more: https://bit.ly/3HL2GQy